/
NXL
$0.34-$0.01 (-3.46%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.6M
22M shares
52-week range
$0.31 – $2.00
2% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
5.37%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1.91
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $207.4K | $242.9K | $144.1K | $1.3M | $110.7K | $168.7K | $301.6K |
| Cost of revenue | $218.2K | $29.0K | $21.4K | $363.2K | $25.7K | $36.6K | $61.4K |
| Gross profit | −$10.8K | $213.9K | $122.6K | $958.1K | $85.1K | $132.1K | $240.3K |
| Gross margin | -5.2% | 88.0% | 85.1% | 72.5% | 76.8% | 78.3% | 79.7% |
| R&D | $0 | $0 | $139.0K | $511.0K | $1.9M | $1.2M | $1.1M |
| Operating income | −$1.5M | −$3.3M | −$6.0M | −$1.8M | −$5.7M | −$7.8M | −$8.4M |
| EBITDA | −$1.5M | −$3.3M | −$6.0M | −$1.6M | −$4.6M | −$7.6M | −$8.2M |
| Net income | −$5.0M | −$3.4M | −$6.1M | −$1.7M | −$4.6M | −$7.6M | −$8.2M |
| Net margin | -2421.2% | -1401.1% | -4218.9% | -128.5% | -4197.6% | -4508.7% | -2725.8% |
| EPS (diluted) | -0.69 | -0.47 | -0.83 | -0.23 | -0.63 | -0.83 | -0.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $345000 | $-0.38 | $-0.38–$-0.38 | 1 |
| 2027 | $690000 | $-0.31 | $-0.31–$-0.31 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nexalin Technology, Inc. Common Stock
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
www.nexalin.com- Employees
- 8
- IPO / List date
- Sep 16, 2022
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds NXL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 10,676 | $3.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NXL yet.
